BaseLaunch Welcomes New Pharmaceutical Partner Takeda
Takeda has officially joined a network of exceptional pharmaceutical companies to support and fund early drug development startups under BaseLaunch. This collaboration marks a significant milestone in the growth of the Basel-based biotech venture incubator.
Enhancing Drug Development with Strategic Partnerships
With Takeda's addition, BaseLaunch now collaborates with six leading pharmaceutical partners, enhancing its capacity to foster promising drug development startups. This partnership not only amplifies funding opportunities but also brings extensive expertise in the biotechnology sector.
The Role of Takeda in Biotech Innovation
Through the strategic investment in BaseLaunch, Takeda taps into a curated deal flow rich in potential within Central Europe’s life sciences arena. This partnership allows BaseLaunch to benefit from Takeda's substantial knowledge in biotech innovation, facilitating better support for its portfolio companies, which have successfully raised over $1 billion (USD) thus far.
A Bright Future for Early-Stage Biotech Ventures
Stephan Emmerth, Director of BaseLaunch, expresses enthusiasm for welcoming Takeda, stating, "This partnership will significantly benefit our early-stage biotech ventures." The access to early funding combined with the company-building capabilities from BaseLaunch propels these ventures towards greater achievements in the biotech landscape.
Successful Track Record of BaseLaunch
Since its inception in 2018, BaseLaunch has successfully supported 27 biotech companies across diverse modalities and indications. Many of these companies are advancing towards Phase II clinical trials, demonstrating the effectiveness of the incubator’s model. Noteworthy achievements include two successful exits, with the acquisition of T3 Pharma for $500 million (USD) by Boehringer Ingelheim.
Collaboration with Leading Biopharmaceutical Companies
BaseLaunch's collaboration extends beyond Takeda. It also includes industry giants like AbbVie, Roche, Novo Nordisk, Johnson & Johnson, and CSL, along with partner venture fund Pureos Bioventures. The collective commitment of these prominent firms is a testament to the success of the BaseLaunch model, embedding the portfolio companies deeply within the vibrant biotech ecosystem of Basel—a recognized hub for biopharma innovation in Europe.
About BaseLaunch
BaseLaunch is an innovative incubator based in Basel that partners with scientists and entrepreneurs to spearhead the development of exceptional biotech ventures focused on groundbreaking therapeutics. The incubator aids company formation from ideation to Series A funding, offering essential support and financing throughout the development process. Through operational guidance from Basel Area Business & Innovation, BaseLaunch emphasizes the region's significance as a leading biotech destination, promoting health tech, MedTech, and pharmaceutical advancements.
Frequently Asked Questions
What is the main purpose of the partnership between BaseLaunch and Takeda?
The partnership aims to enhance support for early-stage biotech ventures by providing funding and expertise in drug development.
How many pharmaceutical companies are currently partnering with BaseLaunch?
BaseLaunch has partnered with six leading pharmaceutical companies including Takeda, AbbVie, Roche, Novo Nordisk, Johnson & Johnson, and CSL.
What achievements has BaseLaunch accomplished since its inception?
BaseLaunch has supported 27 biotech companies, several of which have entered Phase II clinical trials, and has had two successful exits.
What role does Takeda play in the BaseLaunch partnership?
Takeda provides funding and helps guide biotech ventures through its expertise in innovation and medicine development.
Where can I find more information about BaseLaunch?
For more information, you can visit their official website at www.baselaunch.ch.
